Aclaris Therapeutics
ACRS
34 hedge funds and large institutions have $276M invested in Aclaris Therapeutics in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 5 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more funds holding
Funds holding: 33 → 34 (+1)
0% less capital invested
Capital invested by funds: $277M → $276M (-$1.25M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$1.21M |
| 2 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$560K |
| 3 |
State Street
Boston,
Massachusetts
|
+$538K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$369K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$344K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$1.04M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$295K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$157K |
| 4 |
EEG
E.E. Geduld
|
-$42.6K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$28K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
New York State Common Retirement Fund
Albany,
New York
| $46K | +$46.8K | +2,449 | New |
|
|
BA
27
BlackRock Advisors
Wilmington,
Delaware
| $37K | – | – | – |
|
|
SO
28
STRS Ohio
Columbus,
Ohio
| $36K | – | – | – |
|
29
Wells Fargo
San Francisco,
California
| $30K | +$3.78K | +198 | +12% |
|
30
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $16K | -$11.1K | -582 | -40% |
|
31
UBS Group
Zurich,
Switzerland
| $12K | +$10K | +524 | +481% |
|
32
BlackRock
New York
| $7K | +$6.67K | +349 | New |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| $4K | -$12K | -626 | -77% |
|
34
Geode Capital Management
Boston,
Massachusetts
| $819 | +$128K | +6,679 | +18% |
|
|
SIM
35
Spark Investment Management
New York
| – | -$1.04M | -38,616 | Closed |
|
|
36
BNP Paribas Financial Markets
Paris,
France
| – | -$28K | -1,038 | Closed |
|
37
Barclays
London,
United Kingdom
| – | -$26K | -1,000 | Closed |
|
38
Morgan Stanley
New York
| – | -$11K | -391 | Closed |
|
39
Bank of America
Charlotte,
North Carolina
| – | -$4K | -139 | Closed |
|
ACRS Hedge Fund Activity: Q1 2016 in Review
34 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2016, worth a combined $276M — down 0.45% from $277M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ACRS positions and 5 closed out — a net gain of 1 holder — while 16 added to existing stakes and 6 trimmed.
The largest buyer was RA Capital Management, adding an estimated $1.21M. The largest seller was Spark Investment Management, exiting entirely with an estimated $1.04M sold.
- 34 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2016, up from 33 in Q4 2015.
- Funds reported $276M of Aclaris Therapeutics stock for Q1 2016, down 0.45% quarter-over-quarter.
- 6 funds opened new Aclaris Therapeutics positions in Q1 2016 and 5 closed out, a net change of +1 holder.
- The largest Aclaris Therapeutics buyer in Q1 2016 was RA Capital Management, an estimated $1.21M added.
- The largest Aclaris Therapeutics seller in Q1 2016 was Spark Investment Management, an estimated $1.04M sold.
Based on aggregated 13F filings for Q1 2016.